Liang Zheng1, Shiwei Tang2, Rui Tang3, Miao Xu1, Xuehua Jiang1, Ling Wang4. 1. Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy, Sichuan University, Chengdu, China. 2. Department of Pharmacy, People's Hospital of Dujiangyan City, Dujiangyan, China. 3. Department of Pharmacy, West China Hospital of Sichuan University, Chengdu, China. 4. Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy, Sichuan University, Chengdu, China. wlin_scu@scu.edu.cn.
Abstract
BACKGROUND AND OBJECTIVE: Quetiapine and aripiprazole are currently prescribed for pregnant women to treat schizophrenia and bipolar disorder. A dramlatic decline in the plasma concentrations of these two drugs was observed if the doses remained fixed throughout pregnancy. This study aims to develop physiologically based pharmacokinetic (PBPK) models to predict the pharmacokinetics of quetiapine, aripiprazole, and the active aripiprazole metabolite dehydroaripiprazole during pregnancy. METHODS: We developed models using a combined 'bottom-up' and 'top-down' strategy. Models were verified by assessing goodness-of-fit plots and ratios of predicted-to-observed pharmacokinetic parameters. To extrapolate to pregnancy, we considered anatomical, physiological, and metabolic alterations. The in silico models were applied to predict steady-state pharmacokinetics in the three stages of pregnancy and to inform dose selection. RESULTS: We successfully constructed PBPK models that accurately predicted the pharmacokinetics of drugs in the adult population. Predictions suggested that the area under the concentration-time curve at steady state in the first, second, and third trimesters, respectively, decreased by 8.7%, 35.0%, and 49.1% for quetiapine and 12.6%, 38.8%, and 60.9% for the active moiety of aripiprazole. The third-trimester plasma concentrations of quetiapine were below the lower limit of the therapeutic range (100 ng/mL) for most of the time interval, and aripiprazole was entirely unable to reach its effective concentration (150 ng/mL). CONCLUSIONS: According to PBPK predictions, the doses should be increased in the latter two trimesters. We generally recommend that women during late pregnancy take at least 2.5- and 2-times their baseline doses of quetiapine and aripiprazole, respectively.
BACKGROUND AND OBJECTIVE: Quetiapine and aripiprazole are currently prescribed for pregnant women to treat schizophrenia and bipolar disorder. A dramlatic decline in the plasma concentrations of these two drugs was observed if the doses remained fixed throughout pregnancy. This study aims to develop physiologically based pharmacokinetic (PBPK) models to predict the pharmacokinetics of quetiapine, aripiprazole, and the active aripiprazole metabolite dehydroaripiprazole during pregnancy. METHODS: We developed models using a combined 'bottom-up' and 'top-down' strategy. Models were verified by assessing goodness-of-fit plots and ratios of predicted-to-observed pharmacokinetic parameters. To extrapolate to pregnancy, we considered anatomical, physiological, and metabolic alterations. The in silico models were applied to predict steady-state pharmacokinetics in the three stages of pregnancy and to inform dose selection. RESULTS: We successfully constructed PBPK models that accurately predicted the pharmacokinetics of drugs in the adult population. Predictions suggested that the area under the concentration-time curve at steady state in the first, second, and third trimesters, respectively, decreased by 8.7%, 35.0%, and 49.1% for quetiapine and 12.6%, 38.8%, and 60.9% for the active moiety of aripiprazole. The third-trimester plasma concentrations of quetiapine were below the lower limit of the therapeutic range (100 ng/mL) for most of the time interval, and aripiprazole was entirely unable to reach its effective concentration (150 ng/mL). CONCLUSIONS: According to PBPK predictions, the doses should be increased in the latter two trimesters. We generally recommend that women during late pregnancy take at least 2.5- and 2-times their baseline doses of quetiapine and aripiprazole, respectively.
Authors: André Dallmann; Ibrahim Ince; Michaela Meyer; Stefan Willmann; Thomas Eissing; Georg Hempel Journal: Clin Pharmacokinet Date: 2017-11 Impact factor: 6.447
Authors: Johan Reutfors; Carolyn E Cesta; Jacqueline M Cohen; Brian T Bateman; Ruth Brauer; Kristjana Einarsdóttir; Anders Engeland; Kari Furu; Mika Gissler; Alys Havard; Sonia Hernandez-Diaz; Krista F Huybrechts; Øystein Karlstad; Maarit K Leinonen; Jiong Li; Kenneth K C Man; Laura Pazzagli; Andrea Schaffer; Tania Schink; Zixuan Wang; Yongfu Yu; Helga Zoega; Gabriella Bröms Journal: Schizophr Res Date: 2020-04-12 Impact factor: 4.939
Authors: Krista F Huybrechts; Sonia Hernández-Díaz; Elisabetta Patorno; Rishi J Desai; Helen Mogun; Sara Z Dejene; Jacqueline M Cohen; Alice Panchaud; Lee Cohen; Brian T Bateman Journal: JAMA Psychiatry Date: 2016-09-01 Impact factor: 21.596
Authors: Lee S Cohen; Adele C Viguera; Kathryn A McInerney; Marlene P Freeman; Alexandra Z Sosinsky; Danna Moustafa; Samantha P Marfurt; Molly A Kwiatkowski; Shannon K Murphy; Adriann M Farrell; David Chitayat; Sonia Hernández-Díaz Journal: Am J Psychiatry Date: 2015-10-06 Impact factor: 18.112
Authors: Sherry Zhao; Mary Gockenbach; Manuela Grimstein; Hari Cheryl Sachs; Mark Mirochnick; Kimberly Struble; Yodit Belew; Jian Wang; Edmund V Capparelli; Brookie M Best; Tamara Johnson; Jeremiah D Momper; Anil R Maharaj Journal: Front Pediatr Date: 2021-10-13 Impact factor: 3.569